CN105434678A - Composition for preventing and/or treating sub-health caused by using of electronic products - Google Patents
Composition for preventing and/or treating sub-health caused by using of electronic products Download PDFInfo
- Publication number
- CN105434678A CN105434678A CN201510953466.8A CN201510953466A CN105434678A CN 105434678 A CN105434678 A CN 105434678A CN 201510953466 A CN201510953466 A CN 201510953466A CN 105434678 A CN105434678 A CN 105434678A
- Authority
- CN
- China
- Prior art keywords
- medicine
- health food
- flos chrysanthemi
- lutein ester
- corii asini
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 239000008280 blood Substances 0.000 claims abstract description 28
- 210000004369 blood Anatomy 0.000 claims abstract description 27
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 24
- 208000002173 dizziness Diseases 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 206010019233 Headaches Diseases 0.000 claims abstract description 12
- 208000002193 Pain Diseases 0.000 claims abstract description 12
- 231100000869 headache Toxicity 0.000 claims abstract description 12
- 230000008961 swelling Effects 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims description 39
- 235000003935 Hippophae Nutrition 0.000 claims description 23
- 241000229143 Hippophae Species 0.000 claims description 23
- 108010052008 colla corii asini Proteins 0.000 claims description 23
- 241000628997 Flos Species 0.000 claims description 22
- 235000013402 health food Nutrition 0.000 claims description 14
- 206010051625 Conjunctival hyperaemia Diseases 0.000 claims description 11
- 206010010726 Conjunctival oedema Diseases 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 206010024264 Lethargy Diseases 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 238000003809 water extraction Methods 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 2
- 235000008429 bread Nutrition 0.000 claims description 2
- 235000012970 cakes Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 235000014510 cooky Nutrition 0.000 claims description 2
- 235000013312 flour Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000014101 wine Nutrition 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 15
- 235000007516 Chrysanthemum Nutrition 0.000 abstract 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 1
- 108010010803 Gelatin Proteins 0.000 abstract 1
- 240000000950 Hippophae rhamnoides Species 0.000 abstract 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 208000019914 Mental Fatigue Diseases 0.000 abstract 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 abstract 1
- 206010042674 Swelling Diseases 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 239000008273 gelatin Substances 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 235000011852 gelatine desserts Nutrition 0.000 abstract 1
- 201000005111 ocular hyperemia Diseases 0.000 abstract 1
- 239000000047 product Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 11
- 230000005855 radiation Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- -1 concentrated Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a composition for preventing and/or treating sub-health caused by using of electronic products. The composition is prepared from the following raw materials in parts by weight: 3 to 5 parts of sea-buckthorn, 0.5 to 1.5 parts of donkey-hide gelatin, 1 to 3 parts of wolfberry, 3 to 5 parts of chrysanthemum, and 0.001 to 0.003 part of lutein ester. The formula is reasonable. The composition can effectively prevent and/or treat sub-health, is capable of prominently relieving the symptoms such as qi and blood deficiency, qi and blood stagnation, dizziness, headache, mental fatigue, red eye, swelling and pain of eyes, and the like, and thus has a wide market prospect.
Description
Technical field
The present invention relates to a kind of composition and method of making the same and the purposes that prevent and/or treat subhealth state, belong to drug world.
Background technology
Subhealth state is a kind of state between Health and Disease, and its high incidence is parallel with the progress of society, causes serious burden on society, has become a hygienic issues that can not be ignored.Bad work, life style or custom, natural environment pollution, bad psychic factor stimulation etc. very easily cause subhealth state, and the subhealth state wherein caused with lasting computation becomes the epidemic diseases in a kind of city just gradually.
Along with the development of society, the progress of science and technology, electronic product gets more and more, and the life of people also more and more be unable to do without electronic product.Electronic product is as desktop computer, and panel computer, mobile phone etc., while offering convenience to the life of people, bring no small harm also to the health of people.Electronic product all has radiation substantially, normal use amount of radiation is little to human influence, but excessively use can make people be chronically exposed in radiation scope, makes health be subject to the impact of radiation, easy insomnia and dreamful sleep, hypomnesis, affect that intelligence, body void are weak, hypoimmunity etc.In addition, the stimulation of electron radiation can cause the contraction of pupil, causes eyestrain, sleepiness, acid swollen, dry and astringent, the symptoms such as shedding tears can appear in severe patient, Light-headedness.Life-time service electronic product easily causes eyes resistance to decline, and easily infects ophthalmic diseases as conjunctivitis, keratitis etc.
At present, the subhealth symptom long-time, life-time service electronic product caused as: insufficiency of vital energy and blood, QI and blood are smooth, dizziness headache, lethargy, eyes are dim-sighted, conjunctival congestion and swelling pain etc. there is no effective medicine.Therefore, for meeting subhealth state patient, the medication demand of the subhealth state patient that especially long-time, life-time service electronic product causes and treatment needs, find a kind of efficiently, safely, have no side effect, the medicine of applicable long-term taking, tool is of great significance.
Summary of the invention
Technical scheme of the present invention there is provided a kind of composition and method of making the same and the purposes that prevent and/or treat subhealth state.
The invention provides a kind of compositions preventing and/or treating subhealth state, the raw material that it comprises following weight proportioning is prepared from:
Fructus Hippophae 3-5 part, Colla Corii Asini 0.5-1.5 part, Fructus Lycii 1-3 part, Flos Chrysanthemi 3-5 part, lutein ester 0.001-0.003 part.
Preferably, the raw material that described compositions comprises following weight proportioning is prepared from:
Fructus Hippophae 3 parts, 0.5 part, Colla Corii Asini, Fructus Lycii 2 parts, Flos Chrysanthemi 5 parts, lutein ester 0.002 part.
Wherein, described compositions adds that Colla Corii Asini, lutein ester are active component by the protogenic medicinal powder of Fructus Hippophae, Fructus Lycii, Flos Chrysanthemi or water or extractive with organic solvent, adds health food or medicine that in food or medicine, acceptable adjuvant or complementary composition are prepared into.
Wherein, described health food is Flour product, bread, cake, cookies, beverage or wine; Described medicine preparation is tablet, powder, pill, capsule, granule or oral liquid.
The invention provides the method preparing described compositions, step is as follows:
Take Fructus Hippophae, Fructus Lycii, Flos Chrysanthemi, directly beat powder or water or organic solvent extraction, filter, concentrated, add Colla Corii Asini, lutein ester, then add acceptable adjuvant or complementary composition in food or medicine and be prepared into health food or medicine.
Preferably, the step preparing described compositions is as follows: get Fructus Hippophae, Fructus Lycii, Flos Chrysanthemi, adds 10 times of water extraction 2 times, merge extractive liquid, concentrated, dry, mix with Colla Corii Asini, lutein ester, then add acceptable adjuvant or complementary composition in food or medicine and be prepared into health food or medicine.
Present invention also offers described compositions and prepare the purposes in the health food or medicine preventing and/or treating subhealth state.
Wherein, described health food or medicine prevent and/or treat that insufficiency of vital energy and blood, QI and blood are smooth, dizziness headache, lethargy, eyes are dim-sighted and/or the health food of conjunctival congestion and swelling pain or medicine.
The present composition is made up of according to specific proportioning Fructus Hippophae, Colla Corii Asini, Fructus Lycii, Flos Chrysanthemi, lutein ester, side's ZHONGJUHUA liver heat removing and eyesight improving, pathogenic fire reducing of getting rid of evils, Fructus Lycii replenishing vital essence to improve eyesight, nourishing the liver and kidney, after both effective alleviation life-time service electronic equipments, eyes is tired, and is monarch drug.Colla Corii Asini is nourshing Yin and drynsessmoistening prescription, enriches blood, and alleviates the insufficiency of vital energy and blood because sitting uses electronic equipment to cause; Fructus Hippophae blood circulation promoting and blood stasis dispelling, promotes qi-blood circulating, and both are also ministerial drug.Lutein ester helps human body and supplements phylloxanthin, and protection eyes are not by excessive phototoxis, and vision protection, fatigue alleviating is adjuvant drug.All medicines share, and effectively can prevent and/or treat subhealth state, especially for a long time, the subhealth state that causes of life-time service electronic product, obviously improve the symptoms such as insufficiency of vital energy and blood, QI and blood are smooth, dizziness headache, lethargy, eyes are dim-sighted, conjunctival congestion and swelling pain.
Present composition compatibility is precise and appropriate, efficient, inexpensive, safe, easy to use, has wide market prospect.
Below by way of detailed description of the invention, the present invention is described in further detail, but do not limit the present invention, the various change that those skilled in the art make according to the present invention and replacement, only otherwise depart from spirit of the present invention, all should belong to the scope of claims of the present invention.
Detailed description of the invention
The preparation of embodiment 1 present composition
Raw material is taken by following weight proportion:
Fructus Hippophae 3g, Colla Corii Asini 0.5g, Fructus Lycii 2g, Flos Chrysanthemi 5g, lutein ester 0.002g
Get above-mentioned raw materials medicine Fructus Hippophae, Fructus Lycii, Flos Chrysanthemi, add 10 times of water extraction 2 times, merge decocting liquid, carry out spraying dry after concentrated, mix with Colla Corii Asini, lutein ester powder, add appropriate amount of auxiliary materials and be prepared into granule.
The preparation of embodiment 2 present composition
Raw material is taken by following weight proportion:
Fructus Hippophae 5g, Colla Corii Asini 0.5g, Fructus Lycii 3g, Flos Chrysanthemi 5g, lutein ester 0.002g
Get above-mentioned raw materials medicine, by each component crushed after being dried, sieve gets the medicated powder of certain particle size, makes bag tea agent or powder, every packed amount 2g after mix homogeneously.
The preparation of embodiment 3 present composition
Raw material is taken by following weight proportion:
Fructus Hippophae 3g, Colla Corii Asini 0.5g, Fructus Lycii 1g, Flos Chrysanthemi 3g, lutein ester 0.001g
Get above-mentioned raw materials medicine Fructus Hippophae, Fructus Lycii, Flos Chrysanthemi, decoct with water 3 times, merge decocting liquid, concentrated, mix with Colla Corii Asini, lutein ester powder, add appropriate amount of auxiliary materials and prepare buccal tablet.
The preparation of embodiment 4 present composition
Raw material is taken by following weight proportion:
Fructus Hippophae 3g, Colla Corii Asini 1.5g, Fructus Lycii 2g, Flos Chrysanthemi 5g, lutein ester 0.003g
Get above-mentioned raw materials medicine Fructus Hippophae, Fructus Lycii, Flos Chrysanthemi, decoct with water 3 times, merge decocting liquid, filter, be concentrated into thick paste, add Colla Corii Asini, lutein ester powder, add appropriate amount of auxiliary materials, be prepared into unguentum.
Beneficial effect of the present invention is proved below by way of specific experiment.
The component screening experiment of experimental example 1 present composition
1. laboratory sample
Of the present invention group: prepare according to embodiment 1;
Contrast groups 1: get Fructus Hippophae 3g, Colla Corii Asini 0.5g, Fructus Lycii 2g, lutein ester 2mg, preparation method is with embodiment 1;
Contrast groups 2: get Fructus Hippophae 3g, Colla Corii Asini 0.5g, Flos Chrysanthemi 5g, lutein ester 2mg, preparation method is the same;
Contrast groups 3: get Fructus Hippophae 3g, Fructus Lycii 2g, Flos Chrysanthemi 5g, lutein ester 2mg, preparation method is the same;
Contrast groups 4: get Colla Corii Asini 0.5g, Fructus Lycii 2g, Flos Chrysanthemi 5g, lutein ester 2mg, preparation method is the same;
Contrast groups 5: get Fructus Hippophae 3g, Colla Corii Asini 0.5g, Fructus Lycii 2g, Flos Chrysanthemi 5g, preparation method is the same.
2. experimental technique
Of the present invention group with contrast groups 1-5 respectively with 1) dizziness headache, conjunctival congestion and swelling pain; 2) lethargy; 3) insufficiency of vital energy and blood; 4) QI and blood is not smooth; 5) dim-sighted 5 symptoms of eyes compare, and often organize and treat 30 people respectively, and everyone is relative medicine 2 times daily, and each 1 bag, often wrap 10g, boiled water is taken after mixing it with water.
3. experimental result
Of the present invention group of table 1 and contrast groups are on the impact of patient's dizziness headache, conjunctival congestion and swelling pain symptom
Of the present invention group of table 2 and contrast groups are on the impact of the dispirited symptom of patient mental
Of the present invention group of table 3 and contrast groups are on the impact of the not enough symptom of patients blood
Of the present invention group of table 4 and contrast groups are on the impact of the not smooth symptom of patients blood
Of the present invention group of table 5 and contrast groups are on the impact of the dim-sighted symptom of patient's eyes
From the above results, the prescription flavour of a drug of contrast groups 1 ~ 5 are comparatively similar to the present invention, under identical dosage, the present composition is to subhealth symptom, as insufficiency of vital energy and blood, QI and blood are not smooth, dizziness headache, lethargy, eyes are dim-sighted, conjunctival congestion and swelling pain etc. has significant remissive treatment effect, be obviously better than contrast groups 1 ~ 5, show that the present composition is by Chinese medicine monarch principle, flavour of a drug compatibility is precise and appropriate, and each flavour of a drug are indispensable.
Experimental example 2 present composition prevents and/or treats the clinical experiment of subhealth state
1. materials and methods
1.1 physical data
Collect patient 187 example meeting inclusive criteria.
1.2 subhealth states accept standard for medical treatment: be long-term, the long-time subhealth state using electronic product to cause through hospital diagnosis, and patients symptomatic comprises: insufficiency of vital energy and blood, QI and blood are smooth, dizziness headache, lethargy, eyes are dim-sighted, conjunctival congestion and swelling pain.
1.3. Therapeutic Method:
The present composition (preparing according to embodiment 1), often wraps 10g, takes after mixing it with water with 100ml boiled water, every day twice, and every 10g granule is equivalent to crude drug 5g, and treatment time is 3-5 days altogether.
1.4 observation index clinical symptoms improvement rates: situation is improved to the related symptoms before and after treatment and analyzes, as: 1) insufficiency of vital energy and blood, QI and blood are not smooth; 2) dizziness headache, lethargy; 3) dim-sighted, the conjunctival congestion and swelling pain of eyes.
1.5 curative effect determinate standard
Effective: transference cure; Effective: remission; Invalid: Symptoms last.
2. therapeutic outcome:
Table 6
Table 7
Table 8
To sum up, present composition compatibility is precise and appropriate, can the subhealth state that causes of effectively long-time, life-time service electronic product, obviously improves the symptoms such as insufficiency of vital energy and blood, QI and blood are smooth, dizziness headache, lethargy, eyes are dim-sighted, conjunctival congestion and swelling pain.The not smooth total effective rate of present composition treatment insufficiency of vital energy and blood, QI and blood is 91%; The total effective rate for the treatment of dizziness headache, lethargy is 97%; Treatment eyes total effective rate that is dim-sighted, conjunctival congestion and swelling pain is 94%, for clinical prevention and/or treatment subhealth state, especially the subhealth state that long-time, life-time service electronic product causes provides a kind of novel drugs efficient, inexpensive, safe, easy to use, has wide market prospect.
Claims (8)
1. prevent and/or treat a compositions for subhealth state, it is characterized in that: the raw material that it comprises following weight proportioning is prepared from:
Fructus Hippophae 3-5 part, Colla Corii Asini 0.5-1.5 part, Fructus Lycii 1-3 part, Flos Chrysanthemi 3-5 part, lutein ester 0.001-0.003 part.
2. compositions according to claim 1, is characterized in that: the raw material that it comprises following weight proportioning is prepared from:
Fructus Hippophae 3 parts, 0.5 part, Colla Corii Asini, Fructus Lycii 2 parts, Flos Chrysanthemi 5 parts, lutein ester 0.002 part.
3. compositions according to claim 1 and 2, it is characterized in that: it adds that Colla Corii Asini, lutein ester are active component by the protogenic medicinal powder of Fructus Hippophae, Fructus Lycii, Flos Chrysanthemi or water or extractive with organic solvent, adds health food or medicine that in food or medicine, acceptable adjuvant or complementary composition are prepared into.
4. pharmaceutical composition according to claim 3, is characterized in that: described health food is Flour product, bread, cake, cookies, beverage or wine; Described medicine preparation is tablet, powder, pill, capsule, granule or oral liquid.
5. prepare the method for the compositions described in claim 1-4 any one, it is characterized in that: step is as follows:
Take Fructus Hippophae, Fructus Lycii, Flos Chrysanthemi, directly beat powder or water or organic solvent extraction, filter, concentrated, add Colla Corii Asini, lutein ester, then add acceptable adjuvant or complementary composition in food or medicine and be prepared into health food or medicine.
6. method according to claim 5, is characterized in that: step is as follows:
Get Fructus Hippophae, Fructus Lycii, Flos Chrysanthemi, add 10 times of water extraction 2 times, merge extractive liquid, filter, concentrated, dry, mix with Colla Corii Asini, lutein ester, then add acceptable adjuvant or complementary composition in food or medicine and be prepared into health food or medicine.
7. the compositions described in claim 1-4 any one is preparing the purposes in the health food or medicine preventing and/or treating subhealth state.
8. purposes according to claim 7, is characterized in that: described health food or medicine prevent and/or treat that insufficiency of vital energy and blood, QI and blood are smooth, dizziness headache, lethargy, eyes are dim-sighted and/or the health food of conjunctival congestion and swelling pain or medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510953466.8A CN105434678A (en) | 2015-12-16 | 2015-12-16 | Composition for preventing and/or treating sub-health caused by using of electronic products |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510953466.8A CN105434678A (en) | 2015-12-16 | 2015-12-16 | Composition for preventing and/or treating sub-health caused by using of electronic products |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105434678A true CN105434678A (en) | 2016-03-30 |
Family
ID=55545609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510953466.8A Pending CN105434678A (en) | 2015-12-16 | 2015-12-16 | Composition for preventing and/or treating sub-health caused by using of electronic products |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105434678A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110338410A (en) * | 2019-08-14 | 2019-10-18 | 郑州福盛康眼科医疗技术有限公司 | A kind of eye health protection product and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101632828A (en) * | 2009-08-26 | 2010-01-27 | 周辉 | Traditional Chinese medicine composition for treating subhealth and preparation method thereof |
| CN102579533A (en) * | 2012-04-01 | 2012-07-18 | 王国恩 | Medicinal preparation for treating sub-health |
| CN105125736A (en) * | 2015-09-07 | 2015-12-09 | 无限极（中国）有限公司 | Composition with effects of protecting liver and improving eyesight and preparation method thereof |
-
2015
- 2015-12-16 CN CN201510953466.8A patent/CN105434678A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101632828A (en) * | 2009-08-26 | 2010-01-27 | 周辉 | Traditional Chinese medicine composition for treating subhealth and preparation method thereof |
| CN102579533A (en) * | 2012-04-01 | 2012-07-18 | 王国恩 | Medicinal preparation for treating sub-health |
| CN105125736A (en) * | 2015-09-07 | 2015-12-09 | 无限极（中国）有限公司 | Composition with effects of protecting liver and improving eyesight and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 郭梦编: "《经络调理与眼部保健》", 30 September 2014, 中国医药科技出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110338410A (en) * | 2019-08-14 | 2019-10-18 | 郑州福盛康眼科医疗技术有限公司 | A kind of eye health protection product and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101716214A (en) | Medical composition containing dandelion extract as well as novel application and preparation method thereof | |
| CN103961556A (en) | Dendrobium officinale oculentum for relieving asthenopia | |
| CN102441070B (en) | Composition for alleviating eye fatigue | |
| CN101129609A (en) | Chrysanthemum powder forimproving acuity of vision | |
| CN102319294A (en) | Double-vanilla preparation and preparation method thereof | |
| CN103989935B (en) | A kind of tranquilizing by nourishing the heart medicated wine and preparation method thereof | |
| CN104491695A (en) | Pharmaceutical composition for treating chloasma | |
| CN105106440B (en) | A kind of Chinese medicine composition for the treatment of headache and dizzy after lumbar anesthesia | |
| CN105362407A (en) | Composition for preventing and/or treating sub-health caused by smoking | |
| CN105434678A (en) | Composition for preventing and/or treating sub-health caused by using of electronic products | |
| CN103479895A (en) | Heart comforting and brain clearing traditional Chinese medicine composition | |
| CN100558374C (en) | A kind of ophthalmic preparation for the treatment of trachoma | |
| CN103006893A (en) | Medicine for treating chronic rhinitis and preparation method thereof | |
| CN102940693A (en) | Medicine composition for treating diabetic foot | |
| CN101961411B (en) | Medicament for treating aphthosis and preparation method thereof | |
| CN101991829B (en) | Medicament for treating stomach illness | |
| CN110339323A (en) | A kind of Chinese medicine composition and its preparation method and application for treating bradycardia | |
| CN109999098A (en) | It is a kind of for treating the traditional Chinese medicine for external application of cancer-related sleep disturbance | |
| CN102716448A (en) | Chinese patent medicine and TCM decoction capable of effectively curing nausea and vomiting | |
| CN102940677A (en) | Medicine composition for treating diabetic foot | |
| CN102961540A (en) | Medicine for treating coronary heart disease and preparation method for same | |
| CN107095977A (en) | A kind of medicament and its pharmaceutical formulation and preparation method with the malicious effect of fire row of dispelling | |
| CN102293891A (en) | Chinese medicine for treating cardiovascular disease and preparation method thereof | |
| CN106361984A (en) | Nine-raw-material blood stanching powder and preparing method and application thereof | |
| CN105853635A (en) | Pharmaceutical composition for treating angina pectoris of coronary heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160330 |